pathogens

MDPI

Brief Report

Helicobacter pylori Neutrophil Activating Protein (HP-NAP) Enhances the Anti-Leishmanial Activity of Canine Macrophages Against *Leishmania infantum*

Gaia Mazza [1,†], Federica Perego [1,†], Sara Coletta [2], Daniela Proverbio [3], Mario Milco D'Elios [4], Donatella Taramelli [5], Marina De Bernard [2], Fabrizio Bruschi [6,*,‡] and Nicoletta Basilico [1,*,‡]

1 Department of Biomedical, Surgical and Dental Sciences, University of Milan, Via Pascal, 36, 20133 Milan, Italy; gaia.mazza@unimi.it (G.M.); federica.perego@unimi.it (F.P.)
2 Department of Biology, University of Padova, Via Ugo Bassi, 58b, 35131 Padova, Italy; sara.coletta@unipd.it (S.C.); marina.debernard@unipd.it (M.D.B.)
3 Department of Veterinary Medicine and Animal Sciences, University of Milan, Via Dell' Università, 6, 26900 Lodi, Italy; daniela.proverbio@unimi.it
4 Department of Molecular and Developmental Medicine, University of Siena, Via Aldo Moro, 2, 53100 Siena, Italy; delios@unisi.it
5 Department of Pharmacological and Biomolecular Sciences, University of Milan, Via Pascal, 36, 20133 Milan, Italy; donatella.taramelli@unimi.it
6 Department of Translational Research, New Technologies in Medicine and Surgery, University of Pisa, Via Savi, 35, 56126 Pisa, Italy
* Correspondence: fabri.brus2@gmail.com (F.B.); nicoletta.basilico@unimi.it (N.B.); Tel.: +39-0250315069 (N.B.)
† These authors contributed equally to this work.
‡ These authors contributed equally to this work.

Abstract

Leishmania infantum is the etiological agent of visceral leishmaniasis (VL) and is linked to cases of cutaneous leishmaniasis in dogs. Dogs often develop severe systemic disease and serve as the primary reservoir of *L. infantum*. Although several vaccine candidates are under development, no vaccine for visceral leishmaniasis has been approved for human use to date. Chemotherapeutic treatment is hampered by toxicity, cost, and the emergence of parasite-resistant strains. Immunotherapy, combining chemotherapy with modulation of Th1 responses, is a promising therapeutic approach. *Helicobacter pylori* neutrophil-activating protein (HP-NAP), an immunomodulatory protein from *Helicobacter pylori*, is known to promote Th1 immune responses. A Th1 response activates macrophage promoting parasite killing, while a Th2 response favors disease progression. Macrophages are central for infection, either eliminating parasites (Th1 response) or supporting their persistence (Th2 response). IL-12 is a crucial cytokine in driving Th1 immunity and counteracting Th2 responses. We therefore investigated the role of HP-NAP in an in vitro model of *L. infantum* macrophage infection. Canine monocyte-derived macrophages from seven dogs were incubated with *L. infantum* promastigotes. More than 85% of macrophages from all donors were infected, with approximately seven amastigotes per cell. HP-NAP treatment significantly reduced all infection parameters and induced IL-12 production. Collectively, these findings suggest that HP-NAP may represent a promising candidate for adjuvant immunotherapies and vaccine development against *L. infantum*.

Keywords: *Leishmania infantum*; canine macrophages; cytokines; *Helicobacter pylori*-neutrophil activating protein (HP-NAP); leishmaniasis

Check for updates

Academic Editor: Kentaro Kato

Received: 12 December 2025
Revised: 23 January 2026
Accepted: 4 February 2026
Published: 7 February 2026

Copyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.

1. Introduction

Leishmaniasis is a vector-borne, zoonotic parasitic disease of major veterinary and public health importance [1]. It is caused by protozoa of the genus *Leishmania*, transmitted to vertebrate hosts by phlebotomine sandflies. Human leishmaniasis is classified as a Neglected Tropical Disease (NTD), primarily present in tropical and subtropical regions, but also endemic in some parts of Europe, particularly within the Mediterranean basin. *Leishmania infantum* is the most prevalent species in this area, responsible for both canine and human diseases. Human leishmaniasis manifests in three distinct clinical forms: cutaneous, mucocutaneous and visceral leishmaniasis (VL). VL, caused by *L. infantum* and *L. donovani*, is the most severe form with high mortality in symptomatic cases if left untreated [2].

Dogs infected with *L. infantum* exhibit a wide spectrum of clinical manifestations, ranging from asymptomatic carriers, still capable of transmitting the parasites to the insect vector [3], to severe visceral disease, characterized by a high parasite burden in multiple organs. They represent the primary peridomestic reservoir of *L. infantum* and play a central role in the zoonotic transmission cycle of the parasite to humans [4].

Leishmania spp. exists as the extracellular promastigote stage in the insect vector, whereas in the vertebrate host, it transforms into an intracellular amastigote form, primarily within macrophages, which represent both the main host cells where the parasite survives and proliferates and the effector cells capable of mediating parasite killing [5]. Resistance to infection is typically associated with a strong Th1-type cell-mediated immune response, characterized by activation of M1 macrophages and production of inflammatory cytokines such as interferon-gamma (IFN-γ), tumor necrosis factor alpha (TNF-α) and Interleukin 12 (IL-12). The pro-inflammatory response of M1 macrophages is characterized by the production of reactive oxygen species (ROS) and nitric oxide (NO), which are toxic to *Leishmania* parasites. In contrast, disease progression is associated with a predominant Th2-type exaggerated response and activation of M2 macrophages, marked by elevated levels of antibodies and cytokines such as TGF-β, but limited parasite control [6]. The balance between protective Th1-driven and non-protective Th2-oriented immune responses determines disease outcome, influencing whether infected dogs remain subclinically infected or develop clinical signs of canine leishmaniasis (CanL) [7].

Despite extensive research and the demonstration of effective cellular immunity, no effective vaccine currently exists for either human or canine leishmaniasis. Multiple vaccine candidates and adjuvants have been tested for CanL, but to date, only two vaccines have been registered and are commercially available. However, current evidence indicates that their protective efficacy remains weak [8,9]. Also, the range of adjuvants currently available remains limited.

Treatment of both human and CanL remains challenging due to the limited number of available drugs, many of which are toxic, costly and increasingly compromised by parasite resistance. None of the available drugs alone are fully effective; therefore, the aim of the treatment is both to reduce the parasite load and concomitantly to enhance *Leishmania*-specific cell-mediated immunity [10]. Recent guidelines recommend that all dogs diagnosed with CanL should be treated with anti-leishmanial drugs and with immunostimulants or with a combination of both [11,12].

Helicobacter pylori neutrophil-activating protein (HP-NAP) is a virulence factor of *H. pylori* initially identified for its ability to enhance neutrophil adhesion to the endothelium and to induce the release of reactive oxygen species (ROS) by neutrophils, hence its designation as a neutrophil activating protein [13]. Subsequent work revealed that HP-NAP acts as a TLR2 agonist on neutrophils and monocytes, inducing the production of IL-12 and IL-23, thereby creating a cytokine milieu that supports Th1 polarization of antigen-specific

T cells [14]. In in vivo models of allergy, cancer, and helminth infections (such as *Trichinella spiralis*), HP-NAP has been shown to redirect immune responses from a Th2-biased profile toward a Th1 phenotype, a shift that is critical for controlling disease progression and shaping protective immunity [15–19]. Despite this clear immunomodulatory potential, its application in other Th1-dependent contexts, such as leishmaniasis, remains largely unexplored. In our current work, we demonstrate that HP-NAP reduces the infection index of *L. infantum*-infected canine macrophages and stimulates the production of IL-12, supporting its application as an adjuvant immunotherapy agent in canine leishmaniasis.

2. Materials and Methods

2.1. Reagents

Roswell Park Memorial Institute (RPMI) 1640 medium, fetal bovine serum (FBS), HEPES and L-glutamine were obtained from EuroClone (Pero, Italy). Schneider Drosophila Medium, Giemsa stain, Griess reagents (sulphanilamide, napthtylenthylenediamine dihydrochloride, phosphoric acid [H_3PO_4]), SDS and N,N-dimethylformamide were purchased from Sigma-Aldrich (Milan, Italy). Canine IL-12 and IL-10 ELISA kits were obtained from R&D Systems (Minneapolis, MN, USA).

HP-NAP was cloned, expressed, and purified from *Bacillus subtilis* to avoid lipopolysaccharide (LPS) contamination, as described previously [20].

2.2. Cultivation of L. infantum

The promastigote stage of *L. infantum* (MHOM/TN/80/IPT1) (WHO international reference strain, kindly provided by Dr. M. Gramiccia and Dr. T. Di Muccio, ISS, Roma, Italy) was cultured at 24 °C in Schneider's Drosophila Medium supplemented with 10% (*v*/*v*) heat-inactivated FBS, 2 mM L-glutamine and 20 mM HEPES (pH 7.4). Stationary-phase parasite cultures were obtained after incubation at 24 °C for 5 days. Cultures were routinely screened for *Mycoplasma* spp. contamination by PCR.

2.3. HP-NAP Toxicity on L. infantum Promastigotes

The complete medium used for the anti-promastigotes activity assay was RPMI-1640 (EuroClone) supplemented with 10% heat-inactivated fetal bovine serum (EuroClone), 20 mM HEPES pH 7.4, and 2 mM L-glutamine. The parasite suspension (5×10^6 parasites/mL) was dispensed into 96-well round-bottom microplates, and HP-NAP (10–20 µg/mL), diluted in complete medium, or complete medium alone, were added to the wells in triplicate. After 72 h of incubation at 23 °C, 20 µL of MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) solution (5 mg/mL in PBS) was added to each well. After 3 h in the dark, the supernatants were discarded and the formazan crystals dissolved in 100 µL of lysing buffer (20% *w*/*v* of a solution of SDS 40% of N,N-dimethylformamide in H_2O). The plates were then read on a Synergy 4 (Biotek®, Agilent Technologies Italia, S.p.a, Cernusco sul Naviglio, Milan, Italy) microplate reader at a test wavelength of 550 nm and at a reference wavelength of 650 nm. Promastigotes were also counted by light microscopy. See Supplementary Figure S1 for the effect of HP-NAP on promastigote viability.

2.4. Isolation of Monocyte-Derived Canine Macrophages

Blood collected from healthy blood donor dogs (N = 7) of different breeds, middle age, and both sexes, was used (Table S1). The blood was collected during routine blood sampling for annual control. According to the University of Milan animal use regulations, formal ethical approval was not needed as dogs were sampled with the informed consent of the owners during routine visits for prophylactic reasons, and the owners gave their

consent for the use of excess blood after routine testing in further studies (EC decision 29 October 2012, renewed with the protocol n 02-2016). Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized whole blood samples through density gradient centrifugation. Briefly, the whole blood was diluted in RPMI-1640 at a 1:1 ratio, overlaid on Ficoll-Hypaque (Sigma-Aldrich, Italy) at a 2:1 ratio of Ficoll:blood and centrifuged at 543× *g* for 30 min at RT. The PBMC ring was collected and washed with RPMI-1640. Isolated PBMC were plated at a density of 2×10^5 cells in Nunc- Lab-Tek chamber slides (Sigma-Aldrich, Milan, Italy) and allowed to adhere for 2 h at 37 °C in an atmosphere of 5% CO_2. Cells were then washed twice with phosphate-buffered saline (PBS) to discard non-adherent cells and then treated with 0.1 µM of PMA (Sigma-Aldrich, Milan, Italy) for 72 h to achieve differentiation into macrophages, as described in the literature for dog monocytes [21].

2.5. Infection of Canine Macrophages

After differentiation, cells were washed with PBS and infected with stationary-phase *L. infantum* promastigotes at a macrophage: promastigote ratio of 1:10. After 3 h, cell monolayers were washed with PBS to remove non-internalized promastigotes and incubated in the presence of HP-NAP (10 or 20 µg/mL) for 72 h. "Uninfected" refers to macrophages cultured in medium alone, without infection. "Control" refers to infected macrophages cultured without HP-NAP treatment. All HP-NAP-treated macrophages were first infected with *L. infantum* before incubation with the protein. At the end of the incubation, the supernatants were collected and stored at −20 °C. Slides were fixed with 100% methanol and stained with Giemsa. Uninfected and infected cells were counted in random fields using an inverted light microscope (Nikon Europe B.V.1181 VX Amstelveen, The Netherlands). The number of parasites/cell was determined by examining three different wells for each treatment group. The results are expressed as percent of infected macrophages and mean number of amastigotes/cell, and the infectivity index was calculated according to the following Equation [22,23]:

$$\text{Infectivity Index} = (\%\ \text{Infected macrophages}) \times (\text{mean number of amastigotes/cell})$$

2.6. Determination of Inflammatory Mediators

The levels of IL-12 or IL-10 in the supernatants of stimulated canine macrophages were determined using commercial ELISA kits following the manufacturing instructions.

2.7. Griess Assay for Nitric Oxide Determination

The presence of nitrites in the supernatants was evaluated using the Griess assay, as previously described [24]. The Griess reagents consisted of a mixture of equal parts of Reagent A (1% [*w*/*v*] sulphanilamide) and Reagent B (0.1% [*w*/*v*] naphthylethylenediamine dihydrochloride, and 2.5% [*w*/*v*] phosphoric acid). Briefly, 100 µL of each supernatant was mixed with an equal volume of Griess reagent mixture and, after 10 min of incubation at room temperature, nitrite levels were measured spectrophotometrically (Synergy 4 microplate reader, Biotek, GE) at 540 nm. A standard curve of $NaNO_2$ was prepared.

2.8. Statistical Analysis

All data were obtained from at least three independent experiments, and the results are shown as mean ± standard deviations. Differences among three or more groups were analyzed for statistical significance by using ordinary one-way ANOVA test followed by post hoc Dunnett's multiple comparison test. Differences between two groups were analyzed by unpaired *t*-test. Statistical significance was set at $p < 0.05$. Statistical analysis was performed using GraphPad Prism 8.0.2 Software (San Diego, CA, USA).

3. Results

3.1. In Vitro Activity of HP-NAP Against Intracellular Amastigotes in Canine Macrophages

Canine-monocyte derived macrophages, isolated from seven different dog donors, were used for this study. Macrophages were infected with *L. infantum* promastigotes for 3 h and subsequently treated with HP-NAP for 72 h. At the end of the treatment the percentage of infected macrophages, the mean number of amastigotes per infected macrophage and the infectivity index of each sample were calculated.

Canine macrophages exhibited strong phagocytic activity, with a mean of 85 ± 11% (range: 66–98%) of infected macrophages. The infection burden was also high, with more than 80% of macrophages containing more than five intracellular parasites per cell. A reduction in the number of infected macrophages was observed after treatment with 10 or 20 µg/mL of HP-NAP. Representative images of Giemsa-stained infected macrophages treated or not with HP-NAP (20 µg/mL) are shown in Figure 1, panels A and B. Figure 1C shows the % of infected macrophages in control and in HP-NAP-treated cells. Treatment with HP-NAP resulted in a reduction in infection, with inhibition effects of 9% (range 15.1–4.6%) and 21% (range: 19.7–6.4%) at 10 and 20 µg/mL of HP-NAP, respectively. A drop in the number of intracellular amastigotes per macrophage was also observed after treatment with HP-NAP (Figure 1C). The mean number of amastigotes per cell in the controls was 7.2 (range 9.7–5.9), whereas it decreased to 5.45 (range 5.3–5.6) and 4.7 (range 3.8–5.6) following treatment with HP-NAP at 10 and 20 µg/mL, respectively, with a significant reduction observed at the 20 µg/mL concentration (p = 0.011) (Figure 1D). Consequently, the infection index (see Section 2.5 for details) also decreased following treatment with HP-NAP, with a significant reduction at 20 µg/mL concentration (p = 0.005) (Figure 1E). The percentage of inhibition was 42.6 (range 33.2–50.7%). The direct effect of HP-NAP was also evaluated against the promastigote stage. A slight and not significant decrease in promastigote viability was observed after treatment with HP-NAP at 20 µg/mL (Figure S1, Supplementary Materials).



Figure 1. *L. infantum* infection of primary canine macrophages. Upon isolation from peripheral blood and differentiation, canine monocyte-derived macrophages were infected with *L. infantum*

promastigotes. "Control" refers to infected macrophages cultured without HP-NAP treatment. After 3 h, cell monolayers were washed with PBS and incubated in complete medium alone or in the presence of HP-NAP (10 μg/mL in N = 4 donors or 20 μg/mL in N = 5 donors) for 72 h. Representative optical images of Giemsa-stained canine macrophages of Control (**A**) and HP-NAP 20 μg/mL treated macrophages (**B**) using a 100× immersion oil objective. Scale bar: 25 μm. The percent of infected macrophages and the number of amastigotes/cell were quantified through Giemsa staining. (**C**) Percent of infected macrophages. (**D**) Mean number of intracellular amastigotes within infected macrophages. (**E**) Infectivity index calculated as % Infected macrophages × number of amastigotes/cell. Data are presented as mean ± SD. Statistical analysis: Ordinary one-way ANOVA followed by Dunnett's post hoc test comparing each condition to Control; *, $p < 0.05$; **, $p < 0.01$.

3.2. In Vitro Production of IL-12 by *L. infantum*-Infected Canine Macrophages

IL-12 was measured in the cell supernatants of control and HP-NAP- treated cells. Macrophages from two out of seven dogs did not produce IL-12 in any of the tested conditions. Constitutive production of IL-12 varied considerably among different donors, with levels ranging from 0.1 to 14.02 pg/mL. Following *L. infantum* infection, mean IL-12 levels approximately doubled compared to uninfected cells, although they remained low and the difference was not statistically significant. However, the production of IL-12 was significantly enhanced in the presence of 20 μg/mL HP-NAP ($p = 0.013$) (Figure 2A). The mean fold increase was 8, ranging between 2.5 and 30 among the five different donors.



Figure 2. IL-12 production in culture supernatants of primary canine macrophages infected with *L. infantum* and treated with HP-NAP. (**A**) IL-12 levels measured in supernatants of macrophages from N = 5 dogs under the following conditions: uninfected macrophages, infected untreated macrophages (control), and infected macrophages treated with HP-NAP 20 μg/mL. (**B**) IL-12 levels measured in supernatants of macrophages from N = 3 dogs under the following conditions: uninfected macrophages, infected untreated macrophages (control), and infected macrophages treated with HP-NAP 10 or 20 μg/mL. Data are presented as mean ± SD. Statistical analysis: Ordinary one-way ANOVA followed by Dunnett's post hoc test comparing each condition to uninfected macrophages; *, $p < 0.05$.

Macrophages from three dog donors were also stimulated with two different doses of HP-NAP, and a dose-dependent induction of IL-12 was observed, although the differences did not reach statistical significance (Figure 2B)

Nitric oxide production was also evaluated. Only macrophages from two out of seven donors stimulated with *L. infantum* produced detectable amounts of nitric oxide (4.67 and 4.92 μM), but only a negligible increase in NO was measured after treatment with HP-NAP 20 μg/mL (5.26 and 5.85 μM) (Supplementary Figure S2). IL-10 levels in all the experiments and samples were below the detection limits of the assay.

4. Discussion

Macrophages are key cells in *Leishmania* infection, as they are capable of either eliminating the parasite or supporting its survival. They also produce cytokines that shape the adaptive immune response: a Th1-polarized profile, characterized by high levels of IL-12, IFN-γ, and TNF-α, promotes parasite clearance, whereas a Th2-skewed response, with elevated IL-10 and IL-4, is detrimental [25]. Therefore, immunomodulators that drive Th1 polarization have the potential to enhance and accelerate parasite elimination and are actively sought. In this preliminary study, we used canine monocyte-derived macrophages infected with *L. infantum* to investigate the effects of HP-NAP, a potent immune modulator, on parasite survival and cytokine production.

The data show that canine macrophages phagocytose *Leishmania* promastigotes with very high efficiency. The percentage of infected macrophages was 85%, with an average of 7.2 parasites per macrophage. This high infection rate has already been reported in previous studies [26]. Macrophages of human, murine, and canine origin indeed show distinct susceptibility to *L. infantum* infection [26], likely due to species-specific receptor repertoires and cell polarization-mediated expression patterns [27]. Furthermore, since infection was assessed 72 h post-infection, the high proportion of infected macrophages may reflect the inability of canine macrophages to control parasite replication over time, thereby allowing substantial parasite proliferation. Treatment with HP-NAP at a concentration of 20 μg/mL, but not at 10 μg/mL, significantly inhibited parasite replication, resulting in a decreased infectivity index.

The immunomodulatory activity of HP-NAP in the same range of doses has already been reported in previous studies [17]. However, to our knowledge, this is the first study evaluating the activity of HP-NAP against *L. infantum* amastigotes. Two key mediators for the control of *Leishmania* infection are represented by reactive oxygen species (ROS) and nitric oxide (NO), leading to the elimination of intracellular parasites. ROS are released during the macrophage oxidative burst, while NO is produced through the induction of nitric oxide synthase (iNOS). It has previously been demonstrated that HP-NAP can induce ROS production by neutrophils and monocytes [13,28]. Since our experiments showed no difference in the induction of NO by HP-NAP, it is plausible that the reduced macrophage infection values observed after HP-NAP treatment were due to ROS induction by macrophages. ROS were not directly measured in this work, but further studies are planned to investigate the mechanisms of intracellular parasite reduction. We tend to exclude the direct effects of HP-NAP on *Leishmania* parasites, since the results shown in Supplementary Figure S1 indicate that HP-NAP does not significantly affect promastigote viability under cell-free conditions. This further supports the idea that the antileishmanial activity observed is mediated by macrophage activation by HP-NAP.

HP-NAP is a TLR2 ligand [29], and a protective role for TLR2 agonists in *L. infantum* infections has been reported [30]. Indeed, TLR2 signaling in macrophages leads to the production of several pro-inflammatory cytokines and other molecules, including, for example, IL-12, TNF-α, and iNOS. Increased expression of TLR2 has been observed on canine monocytes and macrophages from dogs naturally infected with *Leishmania*, suggesting its involvement in the immune response to the parasites [31]. Our data are consistent with the above observations, as treatment of *L. infantum*-infected macrophages with HP-NAP induced a significant, dose-dependent increase in IL-12 production. Induction of IL-12 plays an important role in promoting protective Th1 immune response; however, *Leishmania* is known to inhibit macrophage IL-12 production as a survival strategy [32,33]. Therefore, modulation of IL-12 production by HP-NAP may represent a potential approach to enhance the host immune responses and to counterbalance the immunosuppression induced by the parasite.

It must be acknowledged that a limitation of this study is represented by the small number of dog donors that have been investigated. This may be responsible for the high dog-to-dog variation seen for cytokine production. Some biological variability was expected since the dogs were not matched for age, sex or breeding; however, the fact that the parasite infectivity and the effect of HP-NAP were similar in all the dogs examined, points toward details in the assay conditions (doses and kinetic of the stimulant, for example) that need to be investigated further and will be addressed in the near future with a larger set of animals.

These results envisage a possible use of HP-NAP as an immunostimulatory tool to be included in candidate vaccine preparation or combined with anti-parasitic drugs.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/pathogens15020184/s1, Table S1: Demographic data of the seven dog donors. Figure S1: Viability of *L. infantum* promastigotes treated with HP-NAP. Figure S2: Nitric oxide (NO) production by canine macrophages infected with *L. infantum* and treated with HP-NAP.

Author Contributions: Conceptualization: G.M., F.P., F.B. and N.B.; Methodology: G.M., F.P. and S.C.; Validation: M.D.B., M.M.D., N.B. and D.P.; Formal analysis: G.M. and F.P.; Investigation: G.M., F.P. and S.C.; Data Curation: G.M. and F.P.; Writing—Original draft preparation: F.P., N.B. and D.T.; Writing—Review and editing: G.M., S.C., D.P., M.D.B., M.M.D. and F.B.; Supervision: D.P., M.D.B., M.M.D., F.B., D.T. and N.B.; Funding acquisition: N.B. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Università degli Studi di Milano (PSR2021, PIANO DI SOSTEGNO ALLA RICERCA 2021). Work partially supported by UNIMI GSA-IDEA Project.

Institutional Review Board Statement: Canine blood was collected during routine blood sampling for annual control. Based on the University of Milan animal use regulations, formal ethical approval was not needed as dogs were sampled with the informed consent of the owners during routine visits for prophy-lactic reasons, and the owners gave their consent for the use of excess blood after routine testing in further studies (EC decision 29 October 2012, renewed with the protocol n 02-2016).

Informed Consent Statement: Informed consent was obtained from owner of animals involved in the study.

Data Availability Statement: The raw data supporting the conclusions of this article will be made available by the authors on request.

Acknowledgments: We gratefully acknowledge the COST Action CA21111 "One Health drugs against parasitic vector borne diseases in Europe and beyond (OneHealthdrugs)", supported by COST (European Cooperation in Science and Technology). The authors would like to thank the Italian Network for Neglected Tropical Diseases for research, dissemination, and advocacy activities in the field of parasitology. We are also grateful to the late Prof. Gianfranco Del Prete for inspiring this study.

Conflicts of Interest: The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:

CanL	Canine leishmaniasis
CL	Cutaneous leishmaniasis
FBS	Fetal Bovine Serum
HP-NAP	*Helicobacter pylori* neutrophil-activating protein
IFN-γ	Interferon gamma
IL-10	Interleukin 10
IL-12	Interleukin 12
IL-23	Interleukin 23

iNOS	Inducible Nitric Oxide Synthase
L	*Leishmania*
NON	Nitric oxideNumber
PBMC	Peripheral Blood Mononuclear Cells
PBS	Phosphate Buffered Saline
PMA	Phorbol Myristate Acetate
ROS	Reactive Oxygen Species
Th1	T helper 1 lymphocytes
Th2	T helper 2 lymphocytes
TLR2	Toll-like receptor 2
TNF-α	Tumor Necrosis Factor alpha
VL	Visceral leishmaniasis

References

1. Bruschi, F.; Gradoni, L. *The Leishmaniases: Old Neglected Tropical Diseases*; Springer International Publishing: Cham, Switzerland, 2018. [CrossRef]
2. WHO. Leishmaniasis. 2024. Available online: https://www.who.int/news-room/fact-sheets/detail/leishmaniasis (accessed on 1 November 2025).
3. Otranto, D.; Dantas-Torres, F. The prevention of canine leishmaniasis and its impact on public health. *Trends Parasitol.* **2013**, *29*, 339–345. [CrossRef] [PubMed]
4. Morales-Yuste, M.; Martin-Sanchez, J.; Corpas-Lopez, V. Canine Leishmaniasis: Update on Epidemiology, Diagnosis, Treatment, and Prevention. *Vet. Sci.* **2022**, *9*, 387. [CrossRef]
5. Hosein, S.; Blake, D.P.; Solano-Gallego, L. Insights on adaptive and innate immunity in canine leishmaniosis. *Parasitology* **2017**, *144*, 95–115. [CrossRef] [PubMed]
6. Samant, M.; Sahu, U.; Pandey, S.C.; Khare, P. Role of Cytokines in Experimental and Human Visceral Leishmaniasis. *Front. Cell. Infect. Microbiol.* **2021**, *11*, 624009. [CrossRef] [PubMed]
7. Ivanescu, L.; Andronic, B.L.; Grigore-Hristodorescu, S.; Martinescu, G.V.; Mindru, R.; Miron, L. The immune response in canine and human leishmaniasis and how this influences the diagnosis—A review and assessment of recent research. *Front. Cell. Infect. Microbiol.* **2023**, *13*, 1326521. [CrossRef]
8. Leite, J.C.; Goncalves, A.A.M.; de Oliveira, D.S.; Resende, L.A.; Boas, D.F.V.; Ribeiro, H.S.; Pereira, D.F.S.; da Silva, A.V.; Mariano, R.; Reis, P.C.C.; et al. Transmission-Blocking Vaccines for Canine Visceral Leishmaniasis: New Progress and Yet New Challenges. *Vaccines* **2023**, *11*, 1565. [CrossRef]
9. Martiniano de Padua, J.A.; Ribeiro, D.; de Aguilar, V.F.F.; Melo, T.F.; Bueno, L.L.; Grossi de Oliveira, A.L.; Fujiwara, R.T.; Keller, K.M. Overview of Commercial Vaccines Against Canine Visceral Leishmaniasis: Current Landscape and Future Directions. *Pathogens* **2025**, *14*, 970. [CrossRef]
10. Saridomichelakis, M.N.; Baneth, G.; Colombo, S.; Dantas-Torres, F.; Ferrer, L.; Fondati, A.; Miro, G.; Ordeix, L.; Otranto, D.; Noli, C. World Association for Veterinary Dermatology Consensus Statement for Diagnosis, and Evidence-Based Clinical Practice Guidelines for Treatment and Prevention of Canine Leishmaniosis. *Vet. Dermatol.* **2025**, *36*, 723–787. [CrossRef]
11. Baxarias, M.; Donato, G.; Mateu, C.; Salichs, M.; Homedes, J.; Miro, G.; Pennisi, M.G.; Solano-Gallego, L. A blinded, randomized and controlled multicenter clinical trial to assess the efficacy and safety of Leisguard((R)) as an immunotherapeutic treatment for healthy Leishmania infantum-seropositive dogs. *Parasit. Vectors* **2023**, *16*, 344. [CrossRef]
12. Miro, G.; Segarra, S.; Ceron, J.J.; Ferrer, L.; Solano-Gallego, L.; Montell, L.; Costa, E.; Teichenne, J.; Marine-Casado, R.; Group, G.t.; et al. New immunomodulatory treatment protocol for canine leishmaniosis reduces parasitemia and proteinuria. *PLoS Negl. Trop. Dis.* **2024**, *18*, e0012712. [CrossRef]
13. Evans, D.J., Jr.; Evans, D.G.; Takemura, T.; Nakano, H.; Lampert, H.C.; Graham, D.Y.; Granger, D.N.; Kvietys, P.R. Characterization of a Helicobacter pylori neutrophil-activating protein. *Infect. Immun.* **1995**, *63*, 2213–2220. [CrossRef]
14. Amedei, A.; Cappon, A.; Codolo, G.; Cabrelle, A.; Polenghi, A.; Benagiano, M.; Tasca, E.; Azzurri, A.; D'Elios, M.M.; Del Prete, G.; et al. The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune responses. *J. Clin. Investig.* **2006**, *116*, 1092–1101. [CrossRef] [PubMed]
15. Codolo, G.; Mazzi, P.; Amedei, A.; Del Prete, G.; Berton, G.; D'Elios, M.M.; de Bernard, M. The neutrophil-activating protein of Helicobacter pylori down-modulates Th2 inflammation in ovalbumin-induced allergic asthma. *Cell. Microbiol.* **2008**, *10*, 2355–2363. [CrossRef]
16. Codolo, G.; Fassan, M.; Munari, F.; Volpe, A.; Bassi, P.; Rugge, M.; Pagano, F.; D'Elios, M.M.; de Bernard, M. HP-NAP inhibits the growth of bladder cancer in mice by activating a cytotoxic Th1 response. *Cancer Immunol. Immunother.* **2012**, *61*, 31–40. [CrossRef]

17. Codolo, G.; Facchinello, N.; Papa, N.; Bertocco, A.; Coletta, S.; Benna, C.; Dall'Olmo, L.; Mocellin, S.; Tiso, N.; de Bernard, M. Macrophage-Mediated Melanoma Reduction after HP-NAP Treatment in a Zebrafish Xenograft Model. *Int. J. Mol. Sci.* **2022**, *23*, 1644. [CrossRef]
18. Chiumiento, L.; Del Prete, G.; Codolo, G.; De Bernard, M.; Amedei, A.; Della Bella, C.; Piazza, M.; D'Elios, S.; Caponi, L.; D'Elios, M.M.; et al. Stimulation of TH1 response by Helicobacter pylori neutrophil activating protein decreases the protective role of IgE and eosinophils in experimental trichinellosis. *Int. J. Immunopathol. Pharmacol.* **2011**, *24*, 895–903. [CrossRef]
19. Ma, J.; Saren, T.; Jin, C.; Kim, H.S.; Contreras Pineda, P.D.; de Bernard, M.; Amini, R.M.; Rondahl, V.; Enblad, G.; Yu, D.; et al. Pre-clinical safety and efficacy evaluation of Helicobacter Pylori neutrophil-activating protein (NAP)-armed CAR-T cells targeting B cell lymphomas. *Cancer Immunol. Immunother.* **2025**, *74*, 262. [CrossRef]
20. Tonello, F.; Dundon, W.G.; Satin, B.; Molinari, M.; Tognon, G.; Grandi, G.; Del Giudice, G.; Rappuoli, R.; Montecucco, C. The Helicobacter pylori neutrophil-activating protein is an iron-binding protein with dodecameric structure. *Mol. Microbiol.* **1999**, *34*, 238–246. [CrossRef]
21. Goto-Koshino, Y.; Ohno, K.; Nakajima, M.; Mochizuki, H.; Kanemoto, H.; Tsujimoto, H. A rapid and simple method to obtain canine peripheral blood-derived macrophages. *J. Vet. Med. Sci.* **2011**, *73*, 773–778. [CrossRef] [PubMed]
22. Gelvez, A.P.C.; Farias, L.H.S.; Pereira, V.S.; da Silva, I.C.M.; Costa, A.C.; Dias, C.; Costa, R.M.R.; da Silva, S.H.M.; Rodrigues, A.P.D. Biosynthesis, characterization and leishmanicidal activity of a biocomposite containing AgNPs-PVP-glucantime. *Nanomedicine* **2018**, *13*, 373–390. [CrossRef] [PubMed]
23. Rodrigues, A.P.; Farias, L.H.; Carvalho, A.S.; Santos, A.S.; do Nascimento, J.L.; Silva, E.O. A novel function for kojic acid, a secondary metabolite from Aspergillus fungi, as antileishmanial agent. *PLoS ONE* **2014**, *9*, e91259. [CrossRef] [PubMed]
24. Corbett, Y.; Parapini, S.; D'Alessandro, S.; Scaccabarozzi, D.; Rocha, B.C.; Egan, T.J.; Omar, A.; Galastri, L.; Fitzgerald, K.A.; Golenbock, D.T.; et al. Involvement of Nod2 in the innate immune response elicited by malarial pigment hemozoin. *Microbes Infect.* **2015**, *17*, 184–194. [CrossRef]
25. Costa-da-Silva, A.C.; Nascimento, D.O.; Ferreira, J.R.M.; Guimaraes-Pinto, K.; Freire-de-Lima, L.; Morrot, A.; Decote-Ricardo, D.; Filardy, A.A.; Freire-de-Lima, C.G. Immune Responses in Leishmaniasis: An Overview. *Trop. Med. Infect. Dis.* **2022**, *7*, 54. [CrossRef]
26. Calvo Alvarez, E.; D'Alessandro, S.; Proverbio, D.; Spada, E.; Perego, R.; Taramelli, D.; Basilico, N.; Parapini, S. In Vitro Antiparasitic Activities of Monovalent Ionophore Compounds for Human and Canine Leishmaniases. *Animals* **2022**, *12*, 2337. [CrossRef]
27. Ueno, N.; Wilson, M.E. Receptor-mediated phagocytosis of Leishmania: Implications for intracellular survival. *Trends Parasitol.* **2012**, *28*, 335–344. [CrossRef]
28. Satin, B.; Del Giudice, G.; Della Bianca, V.; Dusi, S.; Laudanna, C.; Tonello, F.; Kelleher, D.; Rappuoli, R.; Montecucco, C.; Rossi, F. The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a protective antigen and a major virulence factor. *J. Exp. Med.* **2000**, *191*, 1467–1476. [CrossRef] [PubMed]
29. D'Elios, M.M.; Amedei, A.; Cappon, A.; Del Prete, G.; de Bernard, M. The neutrophil-activating protein of Helicobacter pylori (HP-NAP) as an immune modulating agent. *FEMS Immunol. Med. Microbiol.* **2007**, *50*, 157–164. [CrossRef]
30. Jafarzadeh, A.; Nemati, M.; Sharifi, I.; Nair, A.; Shukla, D.; Chauhan, P.; Khorramdelazad, H.; Sarkar, A.; Saha, B. Leishmania species-dependent functional duality of toll-like receptor 2. *IUBMB Life* **2019**, *71*, 1685–1700. [CrossRef] [PubMed]
31. Amorim, I.F.; Silva, S.M.; Figueiredo, M.M.; Moura, E.P.; Castro, R.S.; Lima, T.K.; Gontijo Nde, F.; Michalick, M.S.; Gollob, K.J.; Tafuri, W.L. Toll receptors type-2 and CR3 expression of canine monocytes and its correlation with immunohistochemistry and xenodiagnosis in visceral leishmaniasis. *PLoS ONE* **2011**, *6*, e27679. [CrossRef]
32. Ricardo-Carter, C.; Favila, M.; Polando, R.E.; Cotton, R.N.; Bogard Horner, K.; Condon, D.; Ballhorn, W.; Whitcomb, J.P.; Yadav, M.; Geister, R.L.; et al. Leishmania major inhibits IL-12 in macrophages by signalling through CR3 (CD11b/CD18) and down-regulation of ETS-mediated transcription. *Parasite Immunol.* **2013**, *35*, 409–420. [CrossRef]
33. Shweash, M.; Adrienne McGachy, H.; Schroeder, J.; Neamatallah, T.; Bryant, C.E.; Millington, O.; Mottram, J.C.; Alexander, J.; Plevin, R. Leishmania mexicana promastigotes inhibit macrophage IL-12 production via TLR-4 dependent COX-2, iNOS and arginase-1 expression. *Mol. Immunol.* **2011**, *48*, 1800–1808. [CrossRef] [PubMed]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.